These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38156185)

  • 1. India's Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative.
    Yadav S; Rawal G; Jeyaraman M
    Cureus; 2023 Nov; 15(11):e49542. PubMed ID: 38156185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. India Declines Patent Extension Application of Bedaquiline: A Remarkable Step Towards Tuberculosis Elimination.
    Yadav S
    Cureus; 2023 Nov; 15(11):e48146. PubMed ID: 38046693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
    Field SK
    Ther Adv Chronic Dis; 2015 Jul; 6(4):170-84. PubMed ID: 26137207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis.
    Subbaraman R; Nathavitharana RR; Satyanarayana S; Pai M; Thomas BE; Chadha VK; Rade K; Swaminathan S; Mayer KH
    PLoS Med; 2016 Oct; 13(10):e1002149. PubMed ID: 27780217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease control implications of India's changing multi-drug resistant tuberculosis epidemic.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    PLoS One; 2014; 9(3):e89822. PubMed ID: 24608234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The making of a public health problem: multi-drug resistant tuberculosis in India.
    Engel NC
    Health Policy Plan; 2013 Jul; 28(4):375-85. PubMed ID: 22865835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era.
    Utpat KV; Rajpurohit R; Desai U
    Lung India; 2023; 40(1):19-23. PubMed ID: 36695254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis.
    Goel D
    J Pharmacol Pharmacother; 2014 Jan; 5(1):76-8. PubMed ID: 24554919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.